Universal HLA Testing: Making It Standard Practice in Every Clinic

In this segment, our panel makes the case for universal HLA-A*02:01 testing in every uveal melanoma patient and gives you the practical tools to make it happen in your practice today. You will hear why no patient should reach metastatic disease without knowing their HLA type, how to order the test, where to send it, and what turnaround time to expect from commercial laboratories. The panel also addresses an important nuance: tumor-based HLA typing from next-generation sequencing panels can provide a preliminary result but should always be confirmed with germline blood testing given documented discordance between tumor and blood results. You will also hear how leading centers have built order sets and templated molecular documentation to drive toward full testing compliance, and why community oncologists may already have access to HLA typing results embedded in panels they are routinely ordering.